Post by icemandios on Mar 21, 2024 12:37:34 GMT
Aspira Women’s Health to Present at the MedInvest Biotech & Pharma Investor Conference
AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference taking place in New York City on April 3-4, 2024. Management will be available for one-on-one meetings with investors who are registered for the conference.
Date: Wednesday, April 3, 2024
Time: 4:20 pm EST
Webcast: Recording of the presentation will be available after the event on Aspira’s IR website
Registration: Click HERE to register and attend the conference
This two-day conference features presentations from more than 40 companies developing and/or commercializing technologies across a broad spectrum of indications – including oncology, immunology, neurology, cardiology, diabetes, infectious, pulmonary, autoimmune, respiratory diseases, urology, endocrinology, dermatology, pain management, and many others. The event also will feature talks from key industry opinion leaders, investor panel discussions, and insightful conversations with the National Cancer Institute on patenting, facilitating collaborations, licensing and technology analysis, and marketing.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
OvaWatch ® and Ova1Plus ® are offered to clinicians as OvaSuite SM . Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is a reflex process of two FDA-cleared tests, Ova1 ® and Overa ® , to assess the risk of ovarian malignancy in women planned for surgery.
Our in-development test pipeline is designed to expand our ovarian cancer portfolio and addresses the tremendous need for noninvasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, our OvaMDx SM risk assessment is designed to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, EndoCheck SM is the first-ever noninvasive test designed to identify endometriomas, one of the most commonly occurring forms of endometriosis. The EndoMDx SM test is designed to combine microRNA and protein biomarkers with patient data to identify all endometriosis.